Marrone Bio Innovations Inc  

(Public, NASDAQ:MBII)   Watch this stock  
Find more results for mbii
1.23
0.00 (0.00%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.85 - 2.30
Open     -
Vol / Avg. 0.00/96,523.00
Mkt cap 38.56M
P/E     -
Div/yield     -
EPS -1.15
Shares 31.35M
Beta 0.26
Inst. own 39%
Dec 18, 2017
Marrone Bio Innovations, Inc. - Special Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -202.18% -221.27%
Operating margin -156.41% -168.49%
EBITD margin - -152.58%
Return on average assets -80.30% -53.03%
Return on average equity - -
Employees 97 -
CDP Score - -

Address

1540 Drew Ave
DAVIS, CA 95618-6320
United States - Map
+1-530-7502800 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Marrone Bio Innovations, Inc. offers bio-based pest management and plant health products. The Company's bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene. Its products are used in both conventional and organic crop production, and are sold to growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens and ornamental plants. It offers Regalia for large-acre row crops, such as corn and soybeans. Its pipeline of early-stage discoveries and product candidates extends across a range of product types for end markets, including herbicides, fungicides, nematicides, insecticides, algaecides (for algae control), molluscicides (for mussel and snail control), and plant growth and plant stress regulators. It is engaged in developing MBI-010, MBI-110, Haven (MBI-505) and MBI-601.

Officers and directors

Robert G. Woods Chairman of the Board
Bio & Compensation  - Reuters
James B. Boyd President, Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Pamela G. Marrone Ph.D. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Linda V. Moore Executive Vice President, General Counsel, Secretary
Age: 69
Bio & Compensation  - Reuters
Brian R. Ahrens Vice President of Sales
Age: 44
Bio & Compensation  - Reuters
Nancy Hood Vice President - Marketing
Age: 55
Bio & Compensation  - Reuters
Timothy B. Johnson Ph.D. Vice President - Field Development and Technical Services
Age: 59
Bio & Compensation  - Reuters
Keith J. Pitts Vice President - Regulatory and Government Affairs
Age: 52
Bio & Compensation  - Reuters
Amit Vasavada Ph.D. Vice President - Research and Development
Age: 61
Bio & Compensation  - Reuters
Kathleen A. Merrigan Ph.D. Director
Age: 56
Bio & Compensation  - Reuters